Why would you build a new lab in anticipation of an influx of Asian and Oz customers if you had no idea of when that might happen?
Printable View
Why would you build a new lab in anticipation of an influx of Asian and Oz customers if you had no idea of when that might happen?
I just do not understand why they did not / could not instigate this sort of clinical study years ago with the Vets, or whoever.. (KP not interested?)
Maybe we and the AUA would have the evidence now instead of forever reading "further evidence required" in the conclusions of independent reviews.
Or will this be a case of too small (n 426 patients) and too late/ slow to give Monitor the legs it needs now before Assure MDX et al gain traction?
Four (free?) tests each at time of monitoring cystoscopy over 12 -24 month period, then collate, review and review some more a few years after final test....), publish, could be looking at 4- 5 years before this will any help?
Good they have the cash reserves to keep plodding on
Making the call to back out on this, can't see the upcoming results making any significant increase to the SP.
Walking away with my original buy in, would have had a bit more in it if we hadn't taken part in the CR.
Its not rocket science to figure out that cash in large lumps, which has been lacking up until the large cash raise, may be required for clinical studies.
Other outfits proposing their particular brand of treatment will have the same costs involved in providing similar data and may take just as long to get it.
There is a very high bar to get to the same level as cxBladder and very little wriggle room for superiority.
Even so with 800,000 patients being monitored for recurrence several times a year in the US there would be plenty of room for all contenders at the top providing they were able to match cxBladder's performance and prove it.
Getting standard of care status would certainly restrict other contenders for some time to come.
PEB are not ever going to capture the entire market and 10% would probably do nicely for PEBs continued existence, further clinical trials and other product development.
Makes you wonder what the other 90% will be doing in the meantime, doesnt it?
Unfortunately we have had to do the same, greatly reduced our holdings to reduce downside exposure. The risk reward at this time is too great. Makes more sense to sell out, then buy back in once/if there is any real traction and progress with real data/figures. Downside SP trend stronger than any upside potential currently. Don't want to be caught in a large sell off after following update if it is not a substantial uplift (which is unlikely). May well see some likeminded trades and a continued downwards push on SP prior to update.